Welcome to our dedicated page for Diamedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DiaMedica Therapeutics Inc. (DMAC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke, DiaMedica uses SEC filings to report material clinical, regulatory, financing and governance events.
Recent Form 8-K filings illustrate how these documents inform investors about key developments. For example, DiaMedica has filed 8-Ks describing an in-person pre-IND meeting with the U.S. Food and Drug Administration for its planned U.S. Phase 2 preeclampsia study, including the FDA’s request for an additional non-clinical embryo-fetal development and pre- and postnatal development study in a rabbit model. Other 8-Ks detail private placement transactions, a Sales Agreement for an at-the-market equity offering program, and the entry into related securities purchase and registration rights agreements.
DiaMedica also uses 8-K filings to furnish quarterly financial results press releases, outline changes in executive leadership such as the appointment of a new Chief Medical Officer, and summarize separation agreements with departing officers. These filings complement the company’s periodic reports, which contain broader discussions of risk factors, clinical trial status, cash resources and operating expenses.
On Stock Titan, users can access DiaMedica’s 10-K annual reports, 10-Q quarterly reports, 8-K current reports and related exhibits as they are posted to EDGAR. AI-generated summaries highlight important sections, such as clinical development updates, capital-raising arrangements, and key contract terms, helping readers quickly understand what each filing means for DM199 and the company’s broader pipeline. Form 4 insider transaction reports, when available, can also be reviewed to see how officers and directors are transacting in DMAC shares.
DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell, from time to time, up to $100.0 million of its common shares through an at-the-market program. TD Cowen will act as sales agent and may receive compensation of up to 3.0% of gross proceeds. Sales are to be made under the company’s Form S-3 shelf registration and may not occur until that registration is declared effective. The agreement contains customary representations, indemnities, and incorporated legal opinions from Pushor Mitchell and Alston & Bird.
DiaMedica Therapeutics filed a shelf registration to offer up to $100,000,000 of common shares, warrants and units and a sales agreement permitting up to $100,000,000 of common shares to be sold from time to time under an agreement with TD Securities (USA) LLC. The company’s lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of KLK1 being developed for preeclampsia (PE) and acute ischemic stroke (AIS); DM199 holds Fast Track designation for AIS and avoids human/animal tissue sourcing.
Clinical progress includes an interim Phase 2 investigator-sponsored PE result (N=28) reporting safe, well-tolerated profiles, rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion and no evidence of placental transfer. DiaMedica plans a U.S. IND submission in the second half of 2025. The Phase 2/3 ReMEDy2 AIS trial is adaptive (target ~300, maximum up to 728 after interim analysis of 200) but is experiencing slower-than-expected site activation and enrollment; the company is expanding internal capabilities and global site filings to mitigate delays.
DiaMedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company developing DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). Interim results from the investigator-sponsored Phase 2 PE Part 1a (N=28) showed DM199 appeared safe and well-tolerated, with no evidence of placental transfer and rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion. Preparations are underway to start Part 1b.
The ReMEDy2 Phase 2/3 adaptive AIS trial is ongoing but experiencing slower-than-expected site activations and enrollment due to staffing shortages, protocol criteria, prior hypotension events, and site retention of patients; the company is expanding its internal clinical team and global site footprint to mitigate delays. The adaptive design targets ~300 participants (interim analysis at 200) with a potential final sample up to 728.
Financially, DiaMedica reported a six-month net loss of $15.4 million, cash and marketable securities of $30.0 million and an accumulated deficit of $155.4 million as of June 30, 2025. In July 2025 the company completed a private placement raising net proceeds of $29.9 million, which management states, together with existing resources, should fund operations for at least the next 12 months. R&D and G&A expenses increased year-over-year as clinical activity expanded.
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended June 30, 2025 and provided a business update via a press release attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is furnished and incorporated by reference into Item 2.02, and expressly notes the information is not "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically referenced. The company’s voting common shares trade on The Nasdaq Stock Market under the symbol DMAC. The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page); the 8-K text itself contains no financial tables or line-item results, so readers must consult Exhibit 99.1 for detailed Q2 2025 figures and commentary.
Amendment No. 2 to Schedule 13G, filed 30 Jul 2025, shows Swedish investment vehicle Trill AB and its beneficial owner Jan Stahlberg now hold 6,764,465 DiaMedica Therapeutics Inc. (DMAC) common shares. The position equals 13.14 % of the company’s outstanding stock, calculated against 42.88 M shares outstanding on 9 May 2025 plus 8.61 M shares expected from a July 2025 private placement. All shares carry shared voting and dispositive power; neither Trill AB nor Stahlberg retains sole authority. The certification states the investment is passive and not intended to influence control. No additional transactions, board actions, or financing terms are disclosed.
DiaMedica Therapeutics Inc. (DMAC) – Form 4 insider transaction: On 07/23/2025, 10% owner and director Jan Stahlberg, through his wholly-owned entity Trill AB, purchased 1,542,857 common shares of DMAC at $3.50 per share (Code “P”).
Following the buy, Stahlberg’s indirect holding via Trill AB rose to 6,764,465 shares. No derivative securities were reported. The filing signals a sizeable capital outlay of roughly $5.4 million, lifting the insider’s stake and reinforcing alignment with public shareholders.
FAQ
What is the current stock price of Diamedica Therapeutics (DMAC)?
What is the market cap of Diamedica Therapeutics (DMAC)?
